{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "marketState": "POSTPOST", "regularMarketChange": 0.34350014, "regularMarketTime": 1683898660, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 28188, "regularMarketPreviousClose": 5.388, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 3483, "averageDailyVolume10Day": 2654, "fiftyTwoWeekLowChange": 5.7315, "fiftyTwoWeekRange": "0.0 - 7.572", "fiftyTwoWeekHighChange": -1.8404999, "fiftyTwoWeekHighChangePercent": -0.24306655, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 7.572, "exchange": "LSE", "shortName": "OMEROS CORP OMEROS ORD SHS", "longName": "Omeros Corporation", "messageBoardId": "finmb_32388", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChangePercent": 6.375281, "regularMarketPrice": 5.7315, "earningsTimestamp": 1683664200, "earningsTimestampStart": 1691405940, "earningsTimestampEnd": 1691755200, "trailingAnnualDividendRate": 0.0, "trailingPE": 0.018259002, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 3.139, "sharesOutstanding": 49009300, "bookValue": 1.364, "fiftyDayAverage": 4.6724806, "fiftyDayAverageChange": 1.0590196, "fiftyDayAverageChangePercent": 0.22665039, "twoHundredDayAverage": 3.8522007, "twoHundredDayAverageChange": 1.8792994, "twoHundredDayAverageChangePercent": 0.48785084, "marketCap": 2509285, "priceToBook": 4.2019796, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1517212800000, "priceHint": 2, "symbol": "0KBU.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "", "sector": "", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 63, "title": "Co-Founder, Chairman, CEO & Pres", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 1794634, "fmt": "1.79M", "longFmt": "1,794,634"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Michael A. Jacobsen", "age": 64, "title": "Chief Accounting Officer, VP of Fin. & Treasurer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": {"raw": 518597, "fmt": "518.6k", "longFmt": "518,597"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 43, "title": "VP, Gen. Counsel & Corp. Sec.", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 503236, "fmt": "503.24k", "longFmt": "503,236"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 59, "title": "Co-Founder", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 65, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 54, "title": "VP of HR", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. J. Steven Whitaker J.D., M.D.", "age": 66, "title": "VP of Clinical Devel. & Chief Medical Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 63, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 52, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Debra K. Bowes M.T", "title": "Chief Bus. Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 5, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}